Literature DB >> 16249715

Safe discontinuation of primary pneumocystis prophylaxis in Southern Indian HIV-infected patients on highly active antiretroviral therapy.

N Kumarasamy, Snigdha Vallabhaneni, Anitha J Cecelia, Kenneth H Mayer, Suniti Solomon, Charles C J Carpenter, Timothy P Flanigan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16249715     DOI： 10.1097/01.qai.0000176591.06549.de

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN： 1525-4135            Impact factor:   3.731


× No keyword cloud information.
  3 in total

1.  Causes and determinants of mortality in HIV-infected adults with tuberculosis: an analysis from the CAMELIA ANRS 1295-CIPRA KH001 randomized trial.

Authors:  Olivier Marcy; Didier Laureillard; Yoann Madec; Sarin Chan; Charles Mayaud; Laurence Borand; Narom Prak; Chindamony Kim; Kim Khemarin Lak; Chanroeurn Hak; Bunnet Dim; Thim Sok; Jean-François Delfraissy; Anne E Goldfeld; François-Xavier Blanc
Journal:  Clin Infect Dis       Date:  2014-04-23       Impact factor: 9.079

2.  Risk of pneumocystosis after early discontinuation of prophylaxis among HIV-infected patients receiving highly active antiretroviral therapy.

Authors:  Chien-Yu Cheng; Mao-Yuan Chen; Szu-Min Hsieh; Wang-Huei Sheng; Hsin-Yun Sun; Yi-Chun Lo; Wen-Chun Liu; Chien-Ching Hung
Journal:  BMC Infect Dis       Date:  2010-05-21       Impact factor: 3.090

3.  Safety of discontinuing cotrimoxazole prophylaxis among HIV infected adults on anti-retroviral therapy in Uganda (COSTOP trial): Design.

Authors:  Zacchaeus Anywaine; Andrew Abaasa; Jonathan Levin; Ronnie Kasirye; Anatoli Kamali; Heiner Grosskurth; Paula Munderi; Andrew Nunn
Journal:  Contemp Clin Trials       Date:  2015-05-22       Impact factor: 2.226
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.